{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:08:58Z","timestamp":1789013338061,"version":"build-2803163510"},"reference-count":100,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2022]]},"DOI":"10.3960\/jslrt.22027","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T22:16:02Z","timestamp":1664316962000},"page":"127-135","source":"Crossref","is-referenced-by-count":19,"title":["Lymphoma Microenvironment in DLBCL and PTCL-NOS: the key to                    uncovering heterogeneity and the potential for stratification"],"prefix":"10.3960","volume":"62","author":[{"given":"Kohta","family":"Miyawaki","sequence":"first","affiliation":[{"name":"Department of Medicine and Biosystemic Science, Kyushu                            University Graduate School of Medical Sciences, Fukuoka,                            Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Sugio","sequence":"additional","affiliation":[{"name":"Department of Medicine and Biosystemic Science, Kyushu                            University Graduate School of Medical Sciences, Fukuoka,                            Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","unstructured":"1 Swerdlow SH, Campo E, Harris NL, et al. WHO                    Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed, Lyon,                    International Agency for Research on Cancer. 2017."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Timmins                            MA,                                Wagner                            SD,                                Ahearne                            MJ. The new                    biology of PTCL-NOS and AITL: current status and future clinical impact. Br J                    Haematol. 2020; 189: 54-66.","DOI":"10.1111\/bjh.16428"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Sehn                            LH,                                Gascoyne                            RD. Diffuse                    large B-cell lymphoma: optimizing outcome in the context of clinical and                    biologic heterogeneity. Blood. 2015; 125: 22-32.","DOI":"10.1182\/blood-2014-05-577189"},{"key":"4","unstructured":"4 Reddy                            A,                                Zhang                            J,                                Davis                            NS                    <i>et al.<\/i> Genetic and functional drivers of diffuse large B cell                    lymphoma. Cell. 2017; 171: 481-494.e15."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Chapuy                            B,                                Stewart                            C,                                Dunford                            AJ                    <i>et al.<\/i> Molecular subtypes of diffuse large B cell lymphoma are                    associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018; 24:                    679-690.","DOI":"10.1038\/s41591-018-0016-8"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Schmitz                            R,                                Wright                            GW,                                Huang                            DW                    <i>et al.<\/i> Genetics and pathogenesis of diffuse large B-cell                    lymphoma. N Engl J Med. 2018; 378: 1396-1407.","DOI":"10.1056\/NEJMoa1801445"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Coccaro                            N,                                Anelli                            L,                                Zagaria                            A                    <i>et al.<\/i> Molecular complexity of diffuse large B-cell lymphoma:                    can it be a roadmap for precision medicine? Cancers (Basel). 2020; 12:                    185.","DOI":"10.3390\/cancers12010185"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Lodhi                            N,                                Tun                            M,                                Nagpal                            P                    <i>et al.<\/i> Biomarkers and novel therapeutic approaches for diffuse                    large B-cell lymphoma in the era of precision medicine. Oncotarget. 2020; 11:                    4045-4073.","DOI":"10.18632\/oncotarget.27785"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Kluin                            PM. bcl-6 in                    lymphoma--Sorting out a wastebasket? N Engl J Med. 1994; 331:                    116-118.","DOI":"10.1056\/NEJM199407143310210"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Scott                            DW,                                Gascoyne                            RD. The tumour                    microenvironment in B cell lymphomas. Nat Rev Cancer. 2014; 14:                    517-534.","DOI":"10.1038\/nrc3774"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Alizadeh                            AA,                                Eisen                            MB,                                Davis                            RE                    <i>et al.<\/i> Distinct types of diffuse large B-cell lymphoma                    identified by gene expression profiling. Nature. 2000; 403:                    503-511.","DOI":"10.1038\/35000501"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Mesin                            L,                                Ersching                            J,                                Victora                            GD. Germinal                    center B cell dynamics. Immunity. 2016; 45: 471-482.","DOI":"10.1016\/j.immuni.2016.09.001"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 De                                Silva                            NS,                                Klein                            U. Dynamics of B                    cells in germinal centres. Nat Rev Immunol. 2015; 15: 137-148.","DOI":"10.1038\/nri3804"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Basso                            K,                                Dalla-Favera                            R. Germinal                    centres and B cell lymphomagenesis. Nat Rev Immunol. 2015; 15:                    172-184.","DOI":"10.1038\/nri3814"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Mintz                            MA,                                Cyster                            JG. T follicular                    helper cells in germinal center B cell selection and lymphomagenesis. Immunol                    Rev. 2020; 296: 48-61.","DOI":"10.1111\/imr.12860"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Lenz                            G,                                Wright                            G,                                Dave                            SS                    <i>et al.<\/i> Stromal gene signatures in large-B-cell lymphomas. N                    Engl J Med. 2008; 359: 2313-2323.","DOI":"10.1056\/NEJMoa0802885"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Lossos                            IS,                                Czerwinski                            DK,                                Alizadeh                            AA                    <i>et al.<\/i> Prediction of survival in diffuse large-B-cell lymphoma                    based on the expression of six genes. N Engl J Med. 2004; 350:                    1828-1837.","DOI":"10.1056\/NEJMoa032520"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Tekin                            N,                                Omidvar                            N,                                Morris                            TP                    <i>et al.<\/i> Protocol for qRT-PCR analysis from formalin fixed                    paraffin embedded tissue sections from diffuse large b-cell lymphoma: validation                    of the six-gene predictor score. Oncotarget. 2016; 7:                    83319-83329.","DOI":"10.18632\/oncotarget.13066"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Meyer                            PN,                                Fu                            K,                                Greiner                            T                    <i>et al.<\/i> The stromal cell marker SPARC predicts for survival in                    patients with diffuse large B-cell lymphoma treated with rituximab. Am J Clin                    Pathol. 2011; 135: 54-61.","DOI":"10.1309\/AJCPJX4BJV9NLQHY"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Brandt                            S,                                Montagna                            C,                                Georgis                            A                    <i>et al.<\/i> The combined expression of the stromal markers                    fibronectin and SPARC improves the prediction of survival in diffuse large                    B-cell lymphoma. Exp Hematol Oncol. 2013; 2: 27.","DOI":"10.1186\/2162-3619-2-27"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Gentles                            AJ,                                Newman                            AM,                                Liu                            CL                    <i>et al.<\/i> The prognostic landscape of genes and infiltrating                    immune cells across human cancers. Nat Med. 2015; 21: 938-945.","DOI":"10.1038\/nm.3909"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Haro                            M,                                Orsulic                            S. A paradoxical                    correlation of cancer-associated fibroblasts with survival outcomes in B-cell                    lymphomas and carcinomas. Front Cell Dev Biol. 2018; 6: 98.","DOI":"10.3389\/fcell.2018.00098"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Marinaccio                            C,                                Ingravallo                            G,                                Gaudio                            F                    <i>et al.<\/i> Microvascular density, CD68 and tryptase expression in                    human Diffuse Large B-Cell Lymphoma. Leuk Res. 2014; 38:                    1374-1377.","DOI":"10.1016\/j.leukres.2014.09.007"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Croci                            GA,                                Au-Yeung                            RKH,                                Reinke                            S                    <i>et al.<\/i> SPARC-positive macrophages are the superior prognostic                    factor in the microenvironment of diffuse large B-cell lymphoma and independent                    of MYC rearrangement and double-\/triple-hit status. Ann Oncol. 2021; 32:                    1400-1409.","DOI":"10.1016\/j.annonc.2021.08.1991"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Lwin                            T,                                Hazlehurst                            LA,                                Li                            Z                    <i>et al.<\/i> Bone marrow stromal cells prevent apoptosis of lymphoma                    cells by upregulation of anti-apoptotic proteins associated with activation of                    NF-\u03baB (RelB\/p52) in non-Hodgkin\u2019s lymphoma cells. Leukemia. 2007; 21:                    1521-1531.","DOI":"10.1038\/sj.leu.2404723"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Singh                            RR,                                Kunkalla                            K,                                Qu                            C                    <i>et al.<\/i> ABCG2 is a direct transcriptional target of hedgehog                    signaling and involved in stroma-induced drug tolerance in diffuse large B-cell                    lymphoma. Oncogene. 2011; 30: 4874-4886.","DOI":"10.1038\/onc.2011.195"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Sangaletti                            S,                                Iannelli                            F,                                Zanardi                            F                    <i>et al.<\/i> Intra-tumour heterogeneity of diffuse large B-cell                    lymphoma involves the induction of diversified stroma-tumour interfaces.                    EBioMedicine. 2020; 61: 103055.","DOI":"10.1016\/j.ebiom.2020.103055"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Gars                            E,                                Butzmann                            A,                                Ohgami                            R,                                Balakrishna                            JP,                                O\u2019Malley                            DP. The life and                    death of the germinal center. Ann Diagn Pathol. 2020; 44:                        151421.","DOI":"10.1016\/j.anndiagpath.2019.151421"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Smith                            JP,                                Burton                            GF,                                Tew                            JG,                                Szakal                            AK. Tingible                    body macrophages in regulation of germinal center reactions. Dev Immunol. 1998;                    6: 285-294.","DOI":"10.1155\/1998\/38923"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Victora                            GD,                                Nussenzweig                            MC. Germinal                    centers. Annu Rev Immunol. 2012; 30: 429-457.","DOI":"10.1146\/annurev-immunol-020711-075032"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Baumann                            I,                                Kolowos                            W,                                Voll                            RE                    <i>et al.<\/i> Impaired uptake of apoptotic cells into tingible body                    macrophages in germinal centers of patients with systemic lupus erythematosus.                    Arthritis Rheum. 2002; 46: 191-201.","DOI":"10.1002\/1529-0131(200201)46:1<191::AID-ART10027>3.0.CO;2-K"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Hasselblom                            S,                                Hansson                            U,                                Sigurdardottir                            M                    <i>et al.<\/i> Expression of CD68+ tumor-associated macrophages in                    patients with diffuse large B-cell lymphoma and its relation to prognosis.                    Pathol Int. 2008; 58: 529-532.","DOI":"10.1111\/j.1440-1827.2008.02268.x"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Cai                            Q,                                Liao                            H,                                Lin                            S                    <i>et al.<\/i> High expression of tumor-infiltrating macrophages                    correlates with poor prognosis in patients with diffuse large B-cell lymphoma.                    Med Oncol. 2012; 29: 2317-2322.","DOI":"10.1007\/s12032-011-0123-6"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Coutinho                            R,                                Clear                            AJ,                                Mazzola                            E                    <i>et al.<\/i> Revisiting the immune microenvironment of diffuse large                    B-cell lymphoma using a tissue microarray and immunohistochemistry: robust                    semi-automated analysis reveals CD3 and FoxP3 as potential predictors of                    response to R-CHOP. Haematologica. 2015; 100: 363-369.","DOI":"10.3324\/haematol.2014.110189"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Riihij\u00e4rvi                            S,                                Fiskvik                            I,                                Taskinen                            M                    <i>et al.<\/i> Prognostic influence of macrophages in patients with                    diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial.                    Haematologica. 2015; 100: 238-245.","DOI":"10.3324\/haematol.2014.113472"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Wada                            N,                                Zaki                            MAA,                                Hori                            Y                    <i>et al.<\/i> Tumour-associated macrophages in diffuse large B-cell                    lymphoma: a study of the Osaka Lymphoma Study Group. Histopathology. 2012; 60:                    313-319.","DOI":"10.1111\/j.1365-2559.2011.04096.x"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Marchesi                            F,                                Cirillo                            M,                                Bianchi                            A                    <i>et al.<\/i> High density of CD68+\/CD163+ tumour-associated                    macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable                    prognostic factors and to poor clinical outcomes in patients with diffuse large                    B-cell lymphoma. Hematol Oncol. 2015; 33: 110-112.","DOI":"10.1002\/hon.2142"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Li                            YL,                                Shi                            ZH,                                Wang                            X,                                Gu                            KS,                                Zhai                            ZM.                    Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma                    and correlation with peripheral absolute monocyte count. BMC Cancer. 2019; 19:                    1049.","DOI":"10.1186\/s12885-019-6208-x"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Nam                            SJ,                                Go                            H,                                Paik                            JH                    <i>et al.<\/i> An increase of M2 macrophages predicts poor prognosis in                    patients with diffuse large B-cell lymphoma treated with rituximab,                    cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk Lymphoma. 2014;                    55: 2466-2476.","DOI":"10.3109\/10428194.2013.879713"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Staiger                            AM,                                Altenbuchinger                            M,                                Ziepert                            M                    <i>et al.<\/i> A novel lymphoma-associated macrophage interaction                    signature (LAMIS) provides robust risk prognostication in diffuse large B-cell                    lymphoma clinical trial cohorts of the DSHNHL. Leukemia. 2020; 34:                    543-552.","DOI":"10.1038\/s41375-019-0573-y"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Kennedy                            DE,                                Clark                            MR. Compartments                    and connections within the germinal center. Front Immunol. 2021; 12:                        659151.","DOI":"10.3389\/fimmu.2021.659151"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Schmid                            JP,                                Canioni                            D,                                Moshous                            D                    <i>et al.<\/i> Clinical similarities and differences of patients with                    X-linked lymphoproliferative syndrome type 1 (XLP-1\/SAP deficiency) versus type                    2 (XLP-2\/XIAP deficiency). Blood. 2011; 117: 1522-1529.","DOI":"10.1182\/blood-2010-07-298372"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Monti                            S,                                Savage                            KJ,                                Kutok                            JL                    <i>et al.<\/i> Molecular profiling of diffuse large B-cell lymphoma                    identifies robust subtypes including one characterized by host inflammatory                    response. Blood. 2005; 105: 1851-1861.","DOI":"10.1182\/blood-2004-07-2947"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Chang                            KC,                                Huang                            GC,                                Jones                            D,                                Lin                            YH. Distribution                    patterns of dendritic cells and T cells in diffuse large B-cell lymphomas                    correlate with prognoses. Clin Cancer Res. 2007; 13: 6666-6672.","DOI":"10.1158\/1078-0432.CCR-07-0504"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Keane                            C,                                Gill                            D,                                Vari                            F                    <i>et al.<\/i> CD4 + tumor infiltrating lymphocytes are prognostic and                    independent of R-IPI in patients with DLBCL receiving R-CHOP                    chemo-immunotherapy. Am J Hematol. 2013; 88: 273-276.","DOI":"10.1002\/ajh.23398"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Li                            L,                                Sun                            R,                                Miao                            Y                    <i>et al.<\/i> PD-1\/PD-L1 expression and interaction by automated                    quantitative immunofluorescent analysis show adverse prognostic impact in                    patients with diffuse large B-cell lymphoma having T-cell infiltration: a study                    from the International DLBCL Consortium Program. Mod Pathol. 2019; 32:                    741-754.","DOI":"10.1038\/s41379-018-0193-5"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Xu                            Y,                                Kroft                            SH,                                McKenna                            RW,                                Aquino                            DB. Prognostic                    significance of tumour-infiltrating T lymphocytes and T-cell subsets in de novo                    diffuse large B-cell lymphoma: a multiparameter flow cytometry study. Br J                    Haematol. 2001; 112: 945-949.","DOI":"10.1046\/j.1365-2141.2001.02649.x"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Ansell                            SM,                                Stenson                            M,                                Habermann                            TM,                                Jelinek                            DF,                                Witzig                            TE. CD4+ T-cell                    immune response to large B-cell non-Hodgkin\u2019s lymphoma predicts patient outcome.                    J Clin Oncol. 2001; 19: 720-726.","DOI":"10.1200\/JCO.2001.19.3.720"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Saleh                            R,                                Elkord                            E. FoxP3+ T                    regulatory cells in cancer: prognostic biomarkers and therapeutic targets.                    Cancer Lett. 2020; 490: 174-185.","DOI":"10.1016\/j.canlet.2020.07.022"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 Farinha                            P,                                Al-Tourah                            A,                                Gill                            K                    <i>et al.<\/i> The architectural pattern of FOXP3-positive T cells in                    follicular lymphoma is an independent predictor of survival and histologic                    transformation. Blood. 2010; 115: 289-295.","DOI":"10.1182\/blood-2009-07-235598"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51 Lee                            AM,                                Clear                            AJ,                                Calaminici                            M                    <i>et al.<\/i> Number of CD4+ cells and location of forkhead box                    protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays                    correlates with outcome. J Clin Oncol. 2006; 24: 5052-5059.","DOI":"10.1200\/JCO.2006.06.4642"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52 \u00c1lvaro                            T,                                Lejeune                            M,                                Salvad\u00f3                            MT                    <i>et al.<\/i> Immunohistochemical patterns of reactive                    microenvironment are associated with clinicobiologic behavior in follicular                    lymphoma patients. J Clin Oncol. 2006; 24: 5350-5357.","DOI":"10.1200\/JCO.2006.06.4766"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53 Sweetenham                            JW,                                Goldman                            B,                                LeBlanc                            ML                    <i>et al.<\/i> Prognostic value of regulatory T cells,                    lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma                    treated before and after the introduction of monoclonal antibody therapy: a                    Southwest Oncology Group Study. Ann Oncol. 2010; 21: 1196-1202.","DOI":"10.1093\/annonc\/mdp460"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54 Wahlin                            BE,                                Aggarwal                            M,                                Montes-Moreno                            S                    <i>et al.<\/i> A unifying microenvironment model in follicular                    lymphoma: outcome is predicted by programmed death-1\u2013positive, regulatory,                    cytotoxic, and helper T cells and macrophages. Clin Cancer Res. 2010; 16:                    637-650.","DOI":"10.1158\/1078-0432.CCR-09-2487"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55 \u00c1lvaro                            T,                                Lejeune                            M,                                Salvad\u00f3                            MT                    <i>et al.<\/i> Outcome in Hodgkin\u2019s lymphoma can be predicted from the                    presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res.                    2005; 11: 1467-1473.","DOI":"10.1158\/1078-0432.CCR-04-1869"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56 Greaves                            P,                                Clear                            A,                                Coutinho                            R                    <i>et al.<\/i> Expression of FOXP3, CD68, and CD20 at diagnosis in the                    microenvironment of classical Hodgkin lymphoma is predictive of outcome. J Clin                    Oncol. 2013; 31: 256-262.","DOI":"10.1200\/JCO.2011.39.9881"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57 Serag                                El-Dien                            MM,                                Abdou                            AG,                                Asaad                            NY, Abd                                El-Wahed                            MM,                                Kora                            MAEHM.                    Intratumoral FOXP3+ regulatory T cells in diffuse large B-cell lymphoma. Appl                    Immunohistochem Mol Morphol. 2017; 25: 534-542.","DOI":"10.1097\/PAI.0000000000000335"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58 Ok                            CY,                                Young                            KH. Checkpoint                    inhibitors in hematological malignancies. J Hematol Oncol. 2017; 10:                    103.","DOI":"10.1186\/s13045-017-0474-3"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59 Kiyasu                            J,                                Miyoshi                            H,                                Hirata                            A                    <i>et al.<\/i> Expression of programmed cell death ligand 1 is                    associated with poor overall survival in patients with diffuse large B-cell                    lymphoma. Blood. 2015; 126: 2193-2201.","DOI":"10.1182\/blood-2015-02-629600"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60 Xing                            W,                                Dresser                            K,                                Zhang                            R                    <i>et al.<\/i> PD-L1 expression in EBV-negative diffuse large B-cell                    lymphoma: clinicopathologic features and prognostic implications. Oncotarget.                    2016; 7: 59976-59986.","DOI":"10.18632\/oncotarget.11045"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61 McCord                            R,                                Bolen                            CR,                                Koeppen                            H                    <i>et al.<\/i> PD-L1 and tumor-associated macrophages in de novo DLBCL.                    Blood Adv. 2019; 3: 531-540.","DOI":"10.1182\/bloodadvances.2018020602"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62 Ansell                            SM,                                Minnema                            MC,                                Johnson                            P                    <i>et al.<\/i> Nivolumab for relapsed\/refractory diffuse large B-cell                    lymphoma in patients ineligible for or having failed autologous transplantation:                    A single-arm, Phase II Study. J Clin Oncol. 2019; 37: 481-489.","DOI":"10.1200\/JCO.18.00766"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63 Chen                            BJ,                                Dashnamoorthy                            R,                                Galera                            P                    <i>et al.<\/i> The immune checkpoint molecules PD-1, PD-L1, TIM-3 and                    LAG-3 in diffuse large B-cell lymphoma. Oncotarget. 2019; 10:                    2030-2040.","DOI":"10.18632\/oncotarget.26771"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64 Varricchi                            G, de                                Paulis                            A,                                Marone                            G,                                Galli                            SJ. Future needs                    in mast cell biology. Int J Mol Sci. 2019; 20: 4397.","DOI":"10.3390\/ijms20184397"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65 Lichterman                            JN,                                Reddy                            SM. Mast cells:                    A new frontier for cancer immunotherapy. Cells. 2021; 10: 1270.","DOI":"10.3390\/cells10061270"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66 Aponte-L\u00f3pez                            A,                                Fuentes-Panan\u00e1                            EM,                                Cortes-Mu\u00f1oz                            D,                                Mu\u00f1oz-Cruz                            S. Mast cell,                    the neglected member of the tumor microenvironment: role in breast cancer. J                    Immunol Res. 2018; 2018: 2584243.","DOI":"10.1155\/2018\/2584243"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67 Hedstr\u00f6m                            G,                                Berglund                            M,                                Molin                            D                    <i>et al.<\/i> Mast cell infiltration is a favourable prognostic factor                    in diffuse large B-cell lymphoma. Br J Haematol. 2007; 138:                    68-71.","DOI":"10.1111\/j.1365-2141.2007.06612.x"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68 Green                            MR. Chromatin                    modifying gene mutations in follicular lymphoma. Blood. 2018; 131:                    595-604.","DOI":"10.1182\/blood-2017-08-737361"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69 Newman                            AM,                                Liu                            CL,                                Green                            MR                    <i>et al.<\/i> Robust enumeration of cell subsets from tissue                    expression profiles. Nat Methods. 2015; 12: 453-457.","DOI":"10.1038\/nmeth.3337"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70 Ciavarella                            S,                                Vegliante                            MC,                                Fabbri                            M                    <i>et al.<\/i> Dissection of DLBCL microenvironment provides a gene                    expression-based predictor of survival applicable to formalin-fixed                    paraffin-embedded tissue. Ann Oncol. 2018; 29: 2363-2370.","DOI":"10.1093\/annonc\/mdy450"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71 Kotlov                            N,                                Bagaev                            A,                                Revuelta                            MV                    <i>et al.<\/i> Clinical and biological subtypes of B-cell lymphoma                    revealed by microenvironmental signatures. Cancer Discov. 2021; 11:                    1468-1489.","DOI":"10.1158\/2159-8290.CD-20-0839"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72 Newman                            AM,                                Steen                            CB,                                Liu                            CL                    <i>et al.<\/i> Determining cell type abundance and expression from bulk                    tissues with digital cytometry. Nat Biotechnol. 2019; 37:                    773-782.","DOI":"10.1038\/s41587-019-0114-2"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73 Steen                            CB,                                Luca                            BA,                                Esfahani                            MS                    <i>et al.<\/i> The landscape of tumor cell states and ecosystems in                    diffuse large B cell lymphoma. Cancer Cell. 2021; 39:                    1422-1437.e10.","DOI":"10.1016\/j.ccell.2021.08.011"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74 Geiss                            GK,                                Bumgarner                            RE,                                Birditt                            B                    <i>et al.<\/i> Direct multiplexed measurement of gene expression with                    color-coded probe pairs. Nat Biotechnol. 2008; 26: 317-325.","DOI":"10.1038\/nbt1385"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75 Veldman-Jones                            MH,                                Brant                            R,                                Rooney                            C                    <i>et al.<\/i> Evaluating robustness and sensitivity of the NanoString                    technologies nCounter platform to enable multiplexed gene expression analysis of                    clinical samples. Cancer Res. 2015; 75: 2587-2593.","DOI":"10.1158\/0008-5472.CAN-15-0262"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76 Omolo                            B,                                Yang                            M,                                Lo                            FY                    <i>et al.<\/i> Adaptation of a RAS pathway activation signature from FF                    to FFPE tissues in colorectal cancer. BMC Med Genomics. 2016; 9:                    65.","DOI":"10.1186\/s12920-016-0225-2"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77 Reis                            PP,                                Waldron                            L,                                Goswami                            RS                    <i>et al.<\/i> mRNA transcript quantification in archival samples using                    multiplexed, color-coded probes. BMC Biotechnol. 2011; 11: 46.","DOI":"10.1186\/1472-6750-11-46"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78 Bondar                            G,                                Xu                            W,                                Elashoff                            D                    <i>et al.<\/i> Comparing NGS and NanoString platforms in peripheral                    blood mononuclear cell transcriptome profiling for advanced heart failure                    biomarker development. J Biol Methods. 2020; 7:                        e123.","DOI":"10.14440\/jbm.2020.300"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79 Talla                            SB,                                Rempel                            E,                                Endris                            V                    <i>et al.<\/i> Immuno-oncology gene expression profiling of                    formalin-fixed and paraffin-embedded clear cell renal cell carcinoma:                    performance comparison of the NanoString nCounter technology with targeted RNA                    sequencing. Genes Chromosomes Cancer. 2020; 59: 406-416.","DOI":"10.1002\/gcc.22843"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80 Pescarmona                            R,                                Belot                            A,                                Villard                            M                    <i>et al.<\/i> Comparison of RT-qPCR and Nanostring in the measurement                    of blood interferon response for the diagnosis of type I interferonopathies.                    Cytokine. 2019; 113: 446-452.","DOI":"10.1016\/j.cyto.2018.10.023"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81 Northcott                            PA,                                Shih                            DJH,                                Remke                            M                    <i>et al.<\/i> Rapid, reliable, and reproducible molecular sub-grouping                    of clinical medulloblastoma samples. Acta Neuropathol. 2012; 123:                    615-626.","DOI":"10.1007\/s00401-011-0899-7"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82 Balko                            JM,                                Cook                            RS,                                Vaught                            DB                    <i>et al.<\/i> Profiling of residual breast cancers after neoadjuvant                    chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat                    Med. 2012; 18: 1052-1059.","DOI":"10.1038\/nm.2795"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83 Wallden                            B,                                Storhoff                            J,                                Nielsen                            T                    <i>et al.<\/i> Development and verification of the PAM50-based Prosigna                    breast cancer gene signature assay. BMC Med Genomics. 2015; 8:                    54.","DOI":"10.1186\/s12920-015-0129-6"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84 Scott                            DW,                                Wright                            GW,                                Williams                            PM                    <i>et al.<\/i> Determining cell-of-origin subtypes of diffuse large                    B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded                    tissue. Blood. 2014; 123: 1214-1217.","DOI":"10.1182\/blood-2013-11-536433"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85 Miyawaki                            K,                                Kato                            K,                                Sugio                            T                    <i>et al.<\/i> A germinal center\u2013associated microenvironmental                    signature reflects malignant phenotype and outcome of DLBCL. Blood Adv. 2022; 6:                    2388-2402.","DOI":"10.1182\/bloodadvances.2021004618"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86 Merritt                            CR,                                Ong                            GT,                                Church                            SE                    <i>et al.<\/i> Multiplex digital spatial profiling of proteins and RNA                    in fixed tissue. Nat Biotechnol. 2020; 38: 586-599.","DOI":"10.1038\/s41587-020-0472-9"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87 Tripodo                            C,                                Zanardi                            F,                                Iannelli                            F                    <i>et al.<\/i> A spatially resolved dark- versus light-zone                    microenvironment signature subdivides germinal center-related aggressive B cell                    lymphomas. iScience. 2020; 23:                    101562.","DOI":"10.1016\/j.isci.2020.101562"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88 Iqbal                            J,                                Weisenburger                            DD,                                Greiner                            TC                    <i>et al.<\/i> Molecular signatures to improve diagnosis in peripheral                    T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma.                    Blood. 2010; 115: 1026-1036.","DOI":"10.1182\/blood-2009-06-227579"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89 Iqbal                            J,                                Wright                            G,                                Wang                            C                    <i>et al.<\/i> Gene expression signatures delineate biological and                    prognostic subgroups in peripheral T-cell lymphoma. Blood. 2014; 123:                    2915-2923.","DOI":"10.1182\/blood-2013-11-536359"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90 Watatani                            Y,                                Sato                            Y,                                Miyoshi                            H                    <i>et al.<\/i> Molecular heterogeneity in peripheral T-cell lymphoma,                    not otherwise specified revealed by comprehensive genetic profiling. Leukemia.                    2019; 33: 2867-2883.","DOI":"10.1038\/s41375-019-0473-1"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91 Sakata-Yanagimoto                            M,                                Fukumoto                            K,                                Karube                            K,                                Chiba                            S. Molecular                    understanding of peripheral T-cell lymphomas, not otherwise specified (PTCL,                    NOS): A complex disease category. J Clin Exp Hematop. 2021; 61:                    61-70.","DOI":"10.3960\/jslrt.20059"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92 Rodr\u00edguez-Pinilla                            SM,                                Atienza                            L,                                Murillo                            C                    <i>et al.<\/i> Peripheral T-cell lymphoma with follicular T-cell                    markers. Am J Surg Pathol. 2008; 32: 1787-1799.","DOI":"10.1097\/PAS.0b013e31817f123e"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93 Swerdlow                            SH,                                Campo                            E,                                Pileri                            SA                    <i>et al.<\/i> The 2016 revision of the World Health Organization                    classification of lymphoid neoplasms. Blood. 2016; 127:                    2375-2390.","DOI":"10.1182\/blood-2016-01-643569"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94 Drieux                            F,                                Ruminy                            P,                                Abdel-Sater                            A                    <i>et al.<\/i> Defining signatures of peripheral T-cell lymphoma with a                    targeted 20-marker gene expression profiling assay. Haematologica. 2020; 105:                    1582-1592.","DOI":"10.3324\/haematol.2019.226647"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95 Krishnan                            C,                                Warnke                            RA,                                Arber                            DA,                                Natkunam                            Y. PD-1                    expression in T-cell lymphomas and reactive lymphoid entities: potential overlap                    in staining patterns between lymphoma and viral lymphadenitis. Am J Surg Pathol.                    2010; 34: 178-189.","DOI":"10.1097\/PAS.0b013e3181cc7e79"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96 Kim                            S,                                Kwon                            D,                                Koh                            J                    <i>et al.<\/i> Clinicopathological features of programmed cell death-1                    and programmed cell death-ligand-1 expression in the tumor cells and tumor                    microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell                    lymphoma not otherwise specified. Virchows Arch. 2020; 477:                    131-142.","DOI":"10.1007\/s00428-020-02790-z"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97 Barta                            SK,                                Zain                            J,                                MacFarlane                            AW                            IV                    <i>et al.<\/i> Phase II Study of the PD-1 inhibitor pembrolizumab for                    the treatment of relapsed or refractory mature T-cell lymphoma. Clin Lymphoma                    Myeloma Leuk. 2019; 19: 356-364.e3.","DOI":"10.1016\/j.clml.2019.03.022"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98 Bennani                            NN,                                Pederson                            LD,                                Atherton                            P                    <i>et al.<\/i> A Phase II Study of nivolumab in patients with relapsed                    or refractory peripheral T-cell lymphoma. Blood. 2019; 134(suppl                        1): 467.","DOI":"10.1182\/blood-2019-126194"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99 Lesokhin                            AM,                                Ansell                            SM,                                Armand                            P                    <i>et al.<\/i> Nivolumab in patients with relapsed or refractory                    hematologic malignancy: preliminary results of a Phase Ib Study. J Clin Oncol.                    2016; 34: 2698-2704.","DOI":"10.1200\/JCO.2015.65.9789"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100 Sugio                            T,                                Miyawaki                            K,                                Kato                            K                    <i>et al.<\/i> Microenvironmental immune cell signatures dictate                    clinical outcomes for PTCL-NOS. Blood Adv. 2018; 2: 2242-2252.","DOI":"10.1182\/bloodadvances.2018018754"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/62\/3\/62_22027\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T05:22:59Z","timestamp":1664601779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/62\/3\/62_22027\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.22027","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"article-number":"22027"}}